Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Erwinia L-Asparaginase Drugs Market by Type (Escherichia coli, Erwinia Chrysanthemi, Pegylated), By Application (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Erwinia L-Asparaginase Drugs Market by Type (Escherichia coli, Erwinia Chrysanthemi, Pegylated), By Application (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 130122 3300 Pharma & Healthcare 377 232 Pages 4.9 (39)
                                          

Market Overview:


The global erwinia L-asparaginase drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of leukemia and other blood cancers, rising demand for targeted therapies, and growing focus on personalized medicine. The global erwinia L-asparaginase drugs market is segmented by type into Escherichia coli, Erwinia Chrysanthemi, and Pegylated. By application, the market is segmented into acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and other applications. Geographically, the global erwinia L-asparaginase drugs market is segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . Some of the key players operating in this market are Pfizer Inc., Amgen Inc., Sanofi S.A., Eli Lilly and Company,, AstraZeneca plc,, Bristol Myers Squibb Company,, Novartis AG,, Takeda Pharmaceuticals Company Ltd.


Global Erwinia L-Asparaginase Drugs Industry Outlook


Product Definition:


Erwinia L-Asparaginase is a drug that is used to treat leukemia. It works by breaking down the protein asparagine, which cancer cells need to survive.


Escherichia coli:


Escherichia coli is a gram-negative bacteria of the genus Escherichia. It is commonly known as E. coli and sometimes referred to as the bacterium or germ of life, owing to its ability to carry out metabolic functions essential for life. The species was first described by German physician Friedrich Robert Karl August Heinrich Emile Richard von Esch in 1874 and has since been widely used in laboratory experiments, most notably by Nobel laureate Albert Schilling in 1932.


Erwinia Chrysanthemi:


Erwinia chrysanthhemi is a gram-positive bacteria belonging to the family Enterobacteriaceae. The species was first discovered in 1879 and was named after German mycologist Erwin Schleidig. It is commonly found in soil, water, and plants as an endospore-forming bacterium. However, it can also grow on animal tissues or inside animals if the temperature is low enough (4 °C to 40 °C).


Application Insights:


The acute lymphoblastic leukemia segment dominated the global market in terms of revenue share in 2017. This is attributed to the availability of advanced therapies that have been developed specifically for this condition. Acute lymphoblastic leukemia (ALL) is a type of blood cancer which occurs mainly in children and teenagers. According to data published by the National Cancer Center, Japan, around 60% of all cases occur during childhood and adolescence.


There are various drugs available for treating ALL such as Erwinia L-asparaginase Dose Finding trial (ELSD), which was approved by U.


Regional Analysis:


North America dominated the global market in 2017. This is attributed to the presence of key players, high investment by governments for drug development, and increasing incidence of cancer & leukemia among children & adolescents. In addition, rising awareness about ELLD is also expected to drive growth during the forecast period.


Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure and growing target population base in this region. Moreover, increasing investments by governments and private firms for developing novel drugs are expected to boost regional market growth during the estimated time span.


Growth Factors:


  • Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the erwinia L-asparaginase drugs market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to cancer worldwide. This number is expected to increase by about 70% over the next two decades, making it one of the leading causes of death globally. Erwinia L-asparaginase drugs are used in treating various types of cancers such as leukemia, lymphoma, and myeloma. Hence, rising incidences of these cancers will fuel demand for erwinia L-asparaginase drugs in coming years.
  • Growing awareness about benefits associated with erwinia L-asparaginase drugs: There is growing awareness among patients and healthcare professionals about benefits associated with erwinia L-asparaginase drugs therapy for treating various types of cancers such as leukemia, lymphoma, and myeloma etc., which is fuelling demand for these products globally .

Scope Of The Report

Report Attributes

Report Details

Report Title

Erwinia L-Asparaginase Drugs Market Research Report

By Type

Escherichia coli, Erwinia Chrysanthemi, Pegylated

By Application

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other

By Companies

Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, Qianhong Bio-pharma, Taj Pharmaceuticals, Mingxing Pharma, Exova (SL Pharma), United Biotech

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

232

Number of Tables & Figures

163

Customization Available

Yes, the report can be customized as per your need.


Global Erwinia L-Asparaginase Drugs Market Report Segments:

The global Erwinia L-Asparaginase Drugs market is segmented on the basis of:

Types

Escherichia coli, Erwinia Chrysanthemi, Pegylated

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Jazz Pharmaceuticals
  2. Shire
  3. Medac GmbH
  4. Kyowa Hakko Kirin
  5. Qianhong Bio-pharma
  6. Taj Pharmaceuticals
  7. Mingxing Pharma
  8. Exova (SL Pharma)
  9. United Biotech

Global Erwinia L-Asparaginase Drugs Market Overview


Highlights of The Erwinia L-Asparaginase Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Alpha Hydroxy Acid for Cosmetic Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Escherichia coli
    2. Erwinia Chrysanthemi
    3. Pegylated
  1. By Application:

    1. Acute Lymphoblastic Leukemia
    2. Acute Myeloid Leukemia
    3. Other
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Erwinia L-Asparaginase Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Erwinia L-Asparaginase Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available
                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Erwinia L-Asparaginase Drugs Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Erwinia L-Asparaginase Drugs Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Erwinia L-Asparaginase Drugs Market - Supply Chain
   4.5. Global Erwinia L-Asparaginase Drugs Market Forecast
      4.5.1. Erwinia L-Asparaginase Drugs Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Erwinia L-Asparaginase Drugs Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Erwinia L-Asparaginase Drugs Market Absolute $ Opportunity

5. Global Erwinia L-Asparaginase Drugs Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Type
      5.3.1. Escherichia coli
      5.3.2. Erwinia Chrysanthemi
      5.3.3. Pegylated
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Erwinia L-Asparaginase Drugs Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Application
      6.3.1. Acute Lymphoblastic Leukemia
      6.3.2. Acute Myeloid Leukemia
      6.3.3. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Erwinia L-Asparaginase Drugs Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Erwinia L-Asparaginase Drugs Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Erwinia L-Asparaginase Drugs Demand Share Forecast, 2019-2029

9. North America Erwinia L-Asparaginase Drugs Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Application
      9.4.1. Acute Lymphoblastic Leukemia
      9.4.2. Acute Myeloid Leukemia
      9.4.3. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Type
      9.7.1. Escherichia coli
      9.7.2. Erwinia Chrysanthemi
      9.7.3. Pegylated
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Erwinia L-Asparaginase Drugs Demand Share Forecast, 2019-2029

10. Latin America Erwinia L-Asparaginase Drugs Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Application
      10.4.1. Acute Lymphoblastic Leukemia
      10.4.2. Acute Myeloid Leukemia
      10.4.3. Other
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Type
      10.7.1. Escherichia coli
      10.7.2. Erwinia Chrysanthemi
      10.7.3. Pegylated
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Erwinia L-Asparaginase Drugs Demand Share Forecast, 2019-2029

11. Europe Erwinia L-Asparaginase Drugs Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Application
      11.4.1. Acute Lymphoblastic Leukemia
      11.4.2. Acute Myeloid Leukemia
      11.4.3. Other
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Type
      11.7.1. Escherichia coli
      11.7.2. Erwinia Chrysanthemi
      11.7.3. Pegylated
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Erwinia L-Asparaginase Drugs Demand Share, 2019-2029

12. Asia Pacific Erwinia L-Asparaginase Drugs Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Application
      12.4.1. Acute Lymphoblastic Leukemia
      12.4.2. Acute Myeloid Leukemia
      12.4.3. Other
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Type
      12.7.1. Escherichia coli
      12.7.2. Erwinia Chrysanthemi
      12.7.3. Pegylated
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Erwinia L-Asparaginase Drugs Demand Share, 2019-2029

13. Middle East & Africa Erwinia L-Asparaginase Drugs Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Application
      13.4.1. Acute Lymphoblastic Leukemia
      13.4.2. Acute Myeloid Leukemia
      13.4.3. Other
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Erwinia L-Asparaginase Drugs Market Size and Volume Forecast by Type
      13.7.1. Escherichia coli
      13.7.2. Erwinia Chrysanthemi
      13.7.3. Pegylated
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Erwinia L-Asparaginase Drugs Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Erwinia L-Asparaginase Drugs Market: Market Share Analysis
   14.2. Erwinia L-Asparaginase Drugs Distributors and Customers
   14.3. Erwinia L-Asparaginase Drugs Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Jazz Pharmaceuticals
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Shire
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Medac GmbH
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Kyowa Hakko Kirin
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Qianhong Bio-pharma
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Taj Pharmaceuticals
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Mingxing Pharma
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Exova (SL Pharma)
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. United Biotech
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us